儿童克罗恩病阿达木单抗主动治疗药物监测与临床缓解
一项非盲随机对照试验纳入78例未用过生物制剂且对阿达木单抗诱导治疗有应答的儿童克罗恩病患者,比较主动监测与被动监测谷浓度对持续无激素临床缓解的影响。
核心结论
- 在儿童克罗恩病随机对照试验中,主动监测阿达木单抗谷浓度并调整剂量和间隔,较被动监测(失去应答后测谷浓度)带来显著更高的无激素临床缓解率。
研究设计与样本
- 非盲随机对照试验,纳入78例6-18岁未用过生物制剂但对阿达木单抗诱导治疗有应答的儿童克罗恩病患者(29%女性,平均年龄14.3±2.6岁),2015年7月至2018年12月在以色列儿童消化科单位进行。
- 患者随机分为主动监测组(第4、8周及之后每8周测谷浓度至第72周,n=38)和被动监测组(失去应答后告知医生谷浓度,n=40)。
- 两组均调整阿达木单抗剂量和间隔以使谷浓度达到5 μg/mL;主要终点为第8周至第72周所有访视持续无激素临床缓解。
关键数值与推荐
- 主动监测组谷浓度在第4、8周及之后每8周测量至第72周;被动监测组在失去应答后测量。
- 两组均调整阿达木单抗剂量和间隔以使谷浓度达到5 μg/mL。
临床怎么用
- 对未用过生物制剂且对阿达木单抗诱导治疗有应答的儿童克罗恩病患者,主动监测谷浓度并调整剂量和间隔可能提高持续无激素临床缓解率。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Proactive monitoring of drug trough concentrations and antibodies against drugs might help determine whether patients are likely to respond to treatment and increase efficacy. We investigated whether proactive drug monitoring is associated with higher rates of clinical remission in pediatric patients with Crohn's disease (CD). METHODS: We performed a nonblinded, randomized controlled trial of 78 children with CD (6-18 years old; 29% female; mean age, 14.3 ± 2.6 years) who had not received prior treatment with a biologic agent but had responded to adalimumab induction therapy, under scheduled monitoring of clinical and biologic measures (based on clinical factors and levels of C-reactive protein and fecal calprotectin), at pediatric gastroenterology units in Israel from July 2015 through December 2018. The patients were randomly assigned to groups that received proactive monitoring (trough concentrations measured at weeks 4 and 8 and then every 8 weeks until week 72, n = 38) or reactive monitoring (physicians were informed of trough concentrations after loss of response, n = 40). In both groups, doses and intervals of adalimumab were adjusted to achieve trough concentrations of 5 μg/mL. The primary endpoint was sustained corticosteroid-free clinical remission at all visits (week 8 through week 72). RESULTS: The primary endpoint was achieved by 31 children (82%) in the proactive group and 19 children (48%) in the reactive group (P = .002). Sixteen patients in the proactive monitoring group (42%) achieved a composite outcome of sustained corticosteroid-free remission, C-reactive protein ≤0.5 mg/dL, and level of fecal calprotectin ≤150 μg/g compared with 5 patients in the reactive monitoring group (12%) (P = .003). By week 72 of treatment, 33 patients in the proactive monitoring group had received adalimumab intensification (87%) compared with 24 patients in the reactive monitoring group (60%) (P = .001). CONCLUSIONS: In a randomized controlled trial of pediatric patients with CD, we found that proactive monitoring of adalimumab trough concentrations and adjustment of doses and intervals resulted in significantly higher rates corticosteroid-free clinical remission than reactive monitoring (measuring trough concentration after loss of response). Clinicaltrials.gov no.: NCT02256462.
引用
- Assa A, Matar M, Turner D, et al. Proactive Monitoring of Adalimumab Trough Concentration Associated With Increased Clinical Remission in Children With Crohn's Disease Compared With Reactive Monitoring. Gastroenterology. 2019. PMID: 31194979. doi:10.1053/j.gastro.2019.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。